Grant David G, Salassa John R, Hinni Michael L, Pearson Bruce W, Hayden Richard E, Perry William C
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Jacksonville, FL 32224, USA.
Otolaryngol Head Neck Surg. 2007 Jun;136(6):900-6. doi: 10.1016/j.otohns.2006.12.015.
The study goal was to report the oncologic outcomes of transoral laser microsurgery (TLM) in the treatment of squamous cell carcinoma of the supraglottic larynx.
A two-center prospective case series analysis.
Thirty-eight patients underwent TLM for previously untreated carcinoma of the supraglottic larynx between 1997 and 2005. Pathological T stages were T1 in 8 (21%), T2 in 14 (37%), T3 in 8 (21%), and T4 in 8 (21%). Twenty-six patients (68%) had neck dissections. Thirteen patients (34%) received adjuvant radiotherapy. The mean follow-up for all patients was 31 months. The 2-year Kaplan-Meier estimates for local control were 97%; locoregional control, 94%; disease-specific survival, 80%; and overall survival, 85%. The overall functional laryngeal preservation rate was 79% (19 of 24).
TLM is a safe and effective treatment for cancer of the supraglottic larynx.
TLM is an emerging strategy in the management of laryngeal cancer.
本研究的目标是报告经口激光显微手术（TLM）治疗声门上型喉鳞状细胞癌的肿瘤学结局。
一项两中心前瞻性病例系列分析。
1997年至2005年间，38例患者接受了TLM治疗声门上型喉癌，此前未经治疗。病理T分期为T1期8例（21%），T2期14例（37%），T3期8例（21%），T4期8例（21%）。26例患者（68%）接受了颈部清扫术。13例患者（34%）接受了辅助放疗。所有患者的平均随访时间为31个月。2年的Kaplan-Meier局部控制率估计为97%；局部区域控制率为94%；疾病特异性生存率为80%；总生存率为85%。喉功能总体保留率为79%（24例中的19例）。
TLM是治疗声门上型喉癌的一种安全有效的方法。
TLM是喉癌治疗中一种新兴的策略。
